Brexpiprazole is a medication being studied as a possible adjunctive treatment for post-traumatic stress disorder (PTSD). The medication was first approved in the United States for the treatment of schizophrenia and as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.
Otsuka is conducting this study to find out about the potential benefits and safety of brexpiprazole which is not currently approved by the US Food and Drug Administration (FDA) for the treatment of PTSD. The use of the drug in this study is considered investigational.
About 733 subjects will be in the study and the study is being done at about 80 research sites in the United States. The total participation time in the study will be up to 17 weeks, including 11 office visits in total and the safety follow up phone visit 3 weeks after study treatment completion.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.